Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem's Q3 Revenues Rise 3 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market Wednesday that its third-quarter revenues increased 3 percent with slight gains for both its life sciences and clinical lab businesses.

The New York-based firm brought in total revenues of $23.8 million for the three-month period ended April 30, compared with $23.1 million for the third quarter of 2009. Its life sciences business contributed $13 million of that revenues, up from $12.4 million year over year. Its clinical lab business had revenues of $10.8 million versus $10.6 million.

Enzo said that the revenue increase for its life science business was due to "a shift from contract revenue to higher-margin products," as well as contributions from Assay Designs, the research kits and reagents maker that the firm purchased in March 2009 for around $12.2 million.

Enzo posted a net loss of $4.6 million, or $.12 per share, compared to a net loss of $4.2 million, or $.11 per share, for Q3 2009.

The firm said that its operating expenses, including SG&A and legal costs, increased 27 percent to 44.8 million. It did not disclose its R&D spending.

Enzo Biochem finished the quarter with $34.4 million in cash, cash equivalents, and short-term investments.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.